(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Israel launches new wave of attacks against Hezbollah in Beirut - 2As cases of a rare, deadly infection rise, doctors worry fewer teens will get vaccinated
- 3Conquering Language Boundaries: Individual Accounts of Multilingualism
- 4Investigating Design and Individual Style: Track down Your Remarkable Look
- 5Falcon 9 rocket launches Starlink satellites before making 550th SpaceX landing (video)
- Hanwha Ocean secures orders worth $866m for five vessels
- Cyprus urges hotels to open up, pours funding into tourism
- Expert advice for new stargazers: How to begin your amateur astronomy journey
- Blue Origin launches New Glenn rocket on company's first NASA-scale science mission
- This Huge Ocean Beast Shifts Sharks’ Evolutionary Timeline
- Huge solar flare no threat to Artemis 2 astronaut launch to the moon, NASA says
- Scientists document a death from a meat allergy tied to certain ticks
- 6 Famous Cell phone Brands All over The Planet
- An Excursion Through Renowned Western Network programs
